Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
5 V. r0 Q2 L* u8 K( }4 D& u
! T$ U3 g/ p& X$ G8 V1 a1 `3 a k- w5 R/ t+ g2 I0 f0 ?1 s
Sub-category:+ I0 I* \' [# Y0 h1 p4 |
Molecular Targets . c3 b$ c9 G5 ]3 g' Z% }9 Z
. E6 @6 N3 }* E4 [
% f# h0 }& h% q6 A/ K; q2 oCategory:6 q; z5 A/ M( M* L! l
Tumor Biology
+ D; i. N8 R# j5 @* s: C
. ]! g+ z( F, N$ y3 z) q" _
) X2 A; N, Q* r8 X- V, p4 V- x1 EMeeting:5 N5 [+ @( D/ O& }' o
2011 ASCO Annual Meeting
9 h3 `5 X' j+ N" r7 n) @4 f, ]8 }
% {& _" a F6 @Session Type and Session Title:( I- P! v. }! b% v
Poster Discussion Session, Tumor Biology + e5 [: X( Y* k3 g! Q
2 O! J- x' G5 p
$ A7 r4 R' o( h+ X9 I/ ?) _Abstract No:, w( d% `: X, V
10517
4 t! `' [' X/ e \# k. U# z( n+ w# q, r. L0 X) t: L
3 B( p; @) S! SCitation:
|. h; i# g1 n7 D# HJ Clin Oncol 29: 2011 (suppl; abstr 10517)
5 y9 c$ k+ {) ^. @7 l7 z* ^7 g/ w3 h- T6 S( v
5 Q; f4 @ _. i* a, N5 e' a
Author(s):
9 X1 u: i: h* e. ]J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
1 K" w0 ?* o% _: _& f8 U1 m8 |. d/ c4 v9 t- M$ I! T# Q
: _8 H1 A; K. D, S6 d
. H" O9 ~8 }9 N) J9 J/ `- Y! Z) W
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
6 X: u- L" L% x! b4 G* X
4 [! f8 j# s5 A' F8 N" g- ], w5 }9 q4 bAbstract Disclosures w( n+ ^9 X3 K
. t a" x' L! U! d7 L; N3 C
Abstract:
- W4 J5 m! ^8 [. i7 w# N1 f! u% Z/ |. b
5 h" o' V7 ]( ]' C4 N
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.# v% O0 ^+ y% j# c- B- e. W8 L( @
, Q# x, q3 S) t
* z4 w% q, N3 Q |
显身卡
